Answers are grounded in this paper and cite their sources.
Levonorgestrel releasing intrauterine system have excellent contraceptive efficacy with simultaneous lowering of menstruation's blood loss. It could be used for therapy of endometrial hyperplasia in perimenopause. In position of gestagen part of the hormone replacement therapy it has high control of endometrial proliferation. It is conjoined with the zero increasing of risk of thromboembolic disease in combination with transdermal oestrogen's application.
No takes yet. Share an insight, caveat, or question.
T Fait (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: